Stay updated on Finerenone in HF with LVEF ≥40% Clinical Trial
Sign up to get notified when there's something new on the Finerenone in HF with LVEF ≥40% Clinical Trial page.

Latest updates to the Finerenone in HF with LVEF ≥40% Clinical Trial page
- CheckyesterdayChange DetectedThe Study Details page has new labels 'Results First Posted' and 'Last Update Posted' in the Study Record Dates, and the '(Estimated)' variants have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check8 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check15 days agoChange DetectedAdded a new author list for the FINEARTS-HF anaemia analysis publication (Eur J Heart Fail. 2025). Removed the 'on behalf of the FINEARTS-HF Committees and Investigators' attribution from the citation.SummaryDifference0.0%

- Check29 days agoChange DetectedThe page now lists a large number of new study locations across the United States, Argentina, Australia, Europe, Asia, and other regions. This expands where participants can enroll and access trial sites.SummaryDifference2%

- Check37 days agoChange DetectedAdded a citation: Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction (JACC Heart Fail. 2025 Dec 6;102779). This publication relates to the trial’s safety profile and expands the context of finerenone use in heart failure.SummaryDifference0.0%

- Check59 days agoChange DetectedPublication section wording updated to clarify that PubMed publications may not be about the study and are automatically filled from PubMed. It also adds a revision note indicating version 3.3.2, replacing the previous version 3.2.0 wording.SummaryDifference0.2%

Stay in the know with updates to Finerenone in HF with LVEF ≥40% Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Finerenone in HF with LVEF ≥40% Clinical Trial page.